CRISPR/Cas3 Platform Developer Locus Biosciences Raises $19M in Series A Financing

Locus Biosciences, developer of a next-generation CRISPR-Cas platform for precision antimicrobials, has closed $19 million in Series A funding designed to fund the company through filing its first IND, as well as a subsequent first-in-human trial.A spinout of North Carolina State University (NCSU) founded in 2015, Locus Biosciences designs and creates novel CRISPR RNAs or “smart bombs” designed to kill antibiotic-resistant “superbugs” by irreversibly destroying the bacter